Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

236 Applying Pharmacogenomics in Therapeutics
26. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse
cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic
review and meta-analysis. JAMA 2008;300:1439–50.
27. Ram FS. Use of theophylline in chronic obstructive pulmonary disease: Examining the
evidence. Current Opinion in Pulmonary Medicine 2006;12:132–9.
28. Sadowska AM, Klebe B, Germonpre P, De Backer WA. Glucocorticosteroids as antioxidants
in treatment of asthma and COPD. New application for an old medication?
Steroids 2007;72:1–6.
29. Gordon J, Panos RJ. Inhaled albuterol/salbutamol and ipratropium bromide and their
combination in the treatment of chronic obstructive pulmonary disease. Expert Opinion
on Drug Metabolism & Toxicology 2010;6:381–92.
30. Dalonzo GE, Jr. Levalbuterol in the treatment of patients with asthma and chronic
obstructive lung disease. The Journal of the American Osteopathic Association
2004;104:288–93.
31. Weber RW, Nelson HS. Pirbuterol hydrochloride: Evaluation of beta adrenergic agonist
activity in reversible obstructive pulmonary disease and congestive heart failure.
Pharmacotherapy 1984;4:1–10.
32. Chung KF. Salmeterol/fluticasone combination in the treatment of COPD. International
Journal of Chronic Obstructive Pulmonary Disease 2006;1:235–42.
33. Keating GM, McCormack PL. Salmeterol/fluticasone propionate: A review of its use in
the treatment of chronic obstructive pulmonary disease. Drugs 2007;67:2383–405.
34. Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic
obstructive pulmonary disease. International Journal of Chronic Obstructive
Pulmonary Disease 2008;3:205–15.
35. King P. Role of arformoterol in the management of COPD. International Journal of
Chronic Obstructive Pulmonary Disease 2008;3:385–91.
36. Yawn BP, Raphiou I, Hurley JS, Dalal AA. The role of fluticasone propionate/ salmeterol
combination therapy in preventing exacerbations of COPD. International Journal of
Chronic Obstructive Pulmonary Disease 2010;5:165–78.
37. Hoogsteden HC, Verhoeven GT, Lambrecht BN, Prins JB. Airway inflammation
in asthma and chronic obstructive pulmonary disease with special emphasis on the
antigen-presenting dendritic cell: Influence of treatment with fluticasone propionate.
Clinical and Experimental Allergy 1999;29(Suppl 2):116–24.
38. Scott LJ. Budesonide/formoterol Turbuhaler(R): A review of its use in chronic obstructive
pulmonary disease. Drugs 2012;72:395–414.
39. Calverley PM, Kuna P, Monso E, et al. Beclomethasone/formoterol in the management
of COPD: A randomised controlled trial. Respiratory Medicine 2010;104:1858–68.
40. Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/formoterol
fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease
(COPD): Results from a 52-week phase III trial in subjects with moderate-to-very severe
COPD. International Journal of Chronic Obstructive Pulmonary Disease 2012;7:57–71.
41. Salloum A, Elbaage TY, Soubani AO. Prednisone for chronic obstructive pulmonary disease.
The New England Journal of Medicine 2003;349:1288–90; author reply 1288–90.
42. Li H, He G, Chu H, Zhao L, Yu H. A step-wise application of methylprednisolone
versus dexamethasone in the treatment of acute exacerbations of COPD. Respirology
2003;8:199–204.
43. Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomized controlled
trial of methylprednisolone in the emergency treatment of acute exacerbations of
COPD. Chest 1989;95:563–7.
44. Nelson HS. Advair: Combination treatment with fluticasone propionate/ salmeterol
in the treatment of asthma. The Journal of Allergy and Clinical Immunology 2001;​
107:398–416.